SynthesisFrontiers in aging neuroscience2026
Diagnostic performance of plasma p-Tau217, p-Tau181, and p-Tau231 across the Alzheimer's disease continuum: a network meta-analysis.
Synthesis in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Blood-based biomarkers (BBMs) are transforming the diagnostic workflow for Alzheimer's disease (AD). However, there is no consensus on the optimal phosphorylated tau (p-tau) isoform (217, 181, or 231) or analytical platform [mass spectrometry (MS) vs. immunoassay (IA)] for clinical implementation across different disease stages. Objective: To systematically compare the diagnostic accuracy and prognostic value of plasma p-tau isoforms using different technical platforms for detecting amyloid- Study selection: Studies reporting diagnostic accuracy [Area Under the Curve (AUC)] of plasma p-tau against cerebrospinal fluid (CSF) or Positron Emission Tomography (PET) standards were included. To ensure statistical independence, overlapping cohorts (e.g., BioFINDER, ADNI) were rigorously screened, selecting only the most comprehensive dataset per cohort. Results: A total of 18 high-quality studies comprising 24 independent datasets and 4,736 participants were included. For detecting Aβ pathology, p-tau217 measured by MS (p217_MS) demonstrated the highest diagnostic accuracy (P-score = 0.86), followed by p-tau217 ratio (p217_Ratio) (P-score = 0.78) and automated immunoassays (P-score = 0.67-0.69), all of which significantly outperformed standard p-tau181 immunoassays (P-score = 0.12). Notably, the p-tau217/Aβ 42 ratio on automated platforms provided a significant incremental AUC gain of 0.025 (95% CI: 0.005 to 0.045; Conclusions and relevance: Plasma p-tau217, particularly when measured by mass spectrometry or as a ratio on fully automated platforms, offers the highest accuracy for AD diagnosis and staging. While p-tau231 may serve as an early indicator of amyloidosis, p-tau217 is the most robust marker for tau pathology and disease progression. These findings support the integration of automated p-tau217 assays into routine clinical care to streamline patient stratification for disease-modifying therapies. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier (CRD420261327845).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.